Overview Java backend roles in 2026 demand strong fundamentals plus expertise in modern frameworks like Spring Boot and ...

US slaps 100% tariffs on patented drugs Tariff exemption for generics shields most Indian drugmakers Sun Pharma faces capped 15% tariffs on innovative products. Did our AI summary help? Indian ...

Novo Nordisk is facing a massive wave of generic competitors to its injectable formulations of GLP-1 agonist semaglutide, used to treat diabetes and obesity, as a key patent in India is due to expire ...

In a significant development for diabetes treatment, Zydus Lifesciences has received final approval from the US Food and Drug Administration (USFDA) for its generic version of dapagliflozin tablets, ...

Danish pharmaceutical giant Novo Nordisk on Tuesday announced price cuts of up to 48% on its blockbuster diabetes and obesity drugs Ozempic and Wegovy in India, weeks after semaglutide—the active ...

Generative artificial intelligence (GenAI) is opening the door for more researchers to conduct consumer studies than ever ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

You probably remember the best interaction you've ever had with a company, and the worst one too. But what makes one customer journey feel effortless, personal and relevant, while another feels slow, ...

Ozempic's and Wegovy's lowest doses of 0.25 mg in India will now be priced at 1,415 rupees ($15.04) for a weekly shot from 2,200 rupees and 2,712 rupees earlier, respectively, Novo Nordisk said in a ...

TORONTO - Anne Welch worked a physically demanding job at her local SPCA — lifting pets, cleaning kennels and walking dogs — until she retired at age 71. With the loss of that physical activity, ...

India is struggling with a rapid surge in type 2 diabetes and obesity. With the expiry of the patent for semaglutide, popularly known by the brand names Ozempic and WeGovy, and the entry of generic ...